UCB nominates new board members
pharmafile | March 26, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | UCB, board members
UCB has nominated Harriet Edelman and Charles-Antoine Janssen to become new members of UCB’s board of directors.
The new nominations come as Karel Boone steps down as the board’s chair. He will be succeeded by fellow board member Gerhard Mayr, at the company’s general assembly meeting next month.
Further changes include the resignation of Alexandre Van Damme from the board, as well as the loss of Thomas Leysen and Gaëtan van de Werve, who have come to the end of their respective terms at the board.
Harriet Edelman is currently vice chairman of Emigrant Bank, the largest privately held bank in the US. She has been with the bank since 2008 and, prior to that, was employed at Avon Products.
Charles-Antoine joined UCB in 2001 where he held several management positions at global and local levels.
Among other responsibilities he was head of business development, general manager of Austria and India, and most recently managed international major markets operations.
Prior to UCB, Charles-Antoine worked for Merrill Lynch in London from 1996-2000 where he was VP of equities research, and later became VP of new derivatives Europe.
Both candidates have been selected with a view to further broaden the skills of the board and to align it with the changing and demanding environment, UCB said.
Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds






